For quality of life (QOL) data to be useful in the clinical management of prostate cancer, they must be accurate, responsive to meaningful change and interpretable. Several QOL and symptom scales have been developed for men with prostate cancer but these scales are clinically underutilized, in part because they have not been constructed for individual diagnosis. Individual diagnosis requires precise measurement of well-defined constructs. Computerized adaptive testing (CAT), with item selection algorithms using item response theory (IRT) is one way - perhaps the only feasible way - to precisely measure QOL and its component dimensions. We propose to bring this technology to the measurement of prostate cancer quality of life (P-QOL). This project has two specific aims: To construct and extend an item bank for P-QOL outcomes; and to develop and pilot P-QOL CAT in clinical settings with prostate cancer patients. To accomplish these aims, we will conduct three projects designed to employ cutting edge measurement science and computer technology. Project 1: Use IRT models to construct an initial item bank of questions measuring urinary function, sexual function, bowel function, pain, appetite/weight, MWB, MWB, and overall QOL. Project 2: Using clinical experts, measurement experts, and patients, acquire items into the bank to fill current item difficulty gaps in measured dimensions and overall QOL. These new and rewritten items will then be administered to men with prostate cancer. Expert review of the summarized data will allow us to refine items in the bank and create new sub-banks as indicated. Project 3: Develop a CAT platform and pilot the use of CAT with prostate cancer patients in clinical settings. This will include a determination of the effect of item context, and measurement precision by comparing CAT-derived measures with measures obtained using a fixed subset of items drawn from the bank, and evaluation of preliminary data on sensitivity to meaningful change.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090386-02
Application #
6589541
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-05-01
Project End
2003-04-30
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Type
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Hung, Michelle E; Lenzini, Stephen B; Stranford, Devin M et al. (2018) Enrichment of Extracellular Vesicle Subpopulations Via Affinity Chromatography. Methods Mol Biol 1740:109-124
Weiner, Adam B; Tsai, Kyle P; Keeter, Mary-Kate et al. (2018) The Influence of Decision Aids on Prostate Cancer Screening Preferences: A Randomized Survey Study. J Urol 200:1048-1055
Nettey, Oluwarotimi S; Walker, Austin J; Keeter, Mary Kate et al. (2018) Self-reported Black race predicts significant prostate cancer independent of clinical setting and clinical and socioeconomic risk factors. Urol Oncol 36:501.e1-501.e8
Xu, Li; Gordon, Ryan; Farmer, Rebecca et al. (2018) Precision therapeutic targeting of human cancer cell motility. Nat Commun 9:2454
Zhang, Qiang; Helfand, Brian T; Carneiro, Benedito A et al. (2018) Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-? Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease. Eur Urol 73:648-652
Pascal, Laura E; Masoodi, Khalid Z; Liu, June et al. (2017) Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia. J Endocrinol 235:123-136
Dominguez, Donye; Ye, Cong; Geng, Zhe et al. (2017) Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer. J Immunol 198:1365-1375
Murphy, A B; Nyame, Y A; Batai, K et al. (2017) Does prostate volume correlate with vitamin D deficiency among men undergoing prostate biopsy? Prostate Cancer Prostatic Dis 20:55-60
Loeb, Stacy; Shin, Sanghyuk S; Broyles, Dennis L et al. (2017) Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. BJU Int 120:61-68
Zhang, Minghui; Dominguez, Donye; Chen, Siqi et al. (2017) WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability. Oncol Lett 14:3580-3586

Showing the most recent 10 out of 209 publications